Methods for the treatment of scn2a-related disorders
AssigneePraxis Precision Medicines, Inc.
InventorKelley Dalby
Life of this patent
Estimating the term…
Abstract
The present disclosure features useful methods to treat a SCN2A-related disorder caused by a gain-of-function SCN2A mutation using an SCN2A inhibitor. The present disclosure also features useful methods to treat a SCN2A-related disorder caused by a loss-of-function SCN2A mutation using an SCN2A enhancer. By monitoring the early onset seizure status of a subject, appropriate treatments can be administered more quickly without having to verify whether the subject has a gain-of-function or loss-of-function SCN2A mutation.
Claims65
A method for treating a subject with a SCN2A-related disorder caused by a gain-of-function SCN2A mutation, the method comprising:
- determining whether the subject has had an early onset seizure;
- and
- administering a SCN2A inhibitor to the subject if the subject has had an early onset seizure,
- wherein the method does not comprise experimentally verifying that the subject's SCN2A mutation as a gain-of-function mutation or confirming that the subject's SCN2A mutation has previously been experimentally verified as a gain-of-function mutation prior to administering the SCN2A inhibitor.
A method for treating a subject with a SCN2A-related disorder caused by a loss-of-function SCN2A mutation, the method comprising:
- determining whether the subject has had an early onset seizure;
- and
- administering a SCN2A enhancer to the subject if the subject has not had an early onset seizure,
- wherein the SCN2A enhancer is administered as a second line therapy or is co-administered with a first line therapy if the subject has infantile spasms, and wherein the method does not comprise experimentally verifying the subject's SCN2A mutation as a loss-of-function mutation or confirming that the subject's SCN2A mutation has previously been experimentally verified as a loss-of-function mutation prior to administering the SCN2A enhancer.
Dependencies are inferred from the claim text.